Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > STERN...SUCKS

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Apr 06, 2021 3:39pm

162 Views

Post# 32943263

RE:STERN...SUCKS

With positive results for Otena to date, I have often wondered what BP actual opinion is of what ATE has done. Do they not see value in what ATE is doing and have accomplished? Does ATE mgmt want a deal at this time or are they holding out for bigger payout. Feeling mgmt is holding their cards kinda close, is it due to current negoitiations? So much to understand, retail is tired of hearing the same plug of "partnering".......Yes, patience is wearing a little thin.